High titer recombinant influenza viruses with enhanced replication in vero cells
The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and genes from vaccine seed virus isolates which include a HA gene segment with a HA2 sequence encoding a HA2 that confers enhanced growth in cells in culture, such as Vero cells.
1. A method to prepare an influenza virus with enhanced replication in Vero cells, comprising:
providing a vector comprising a recombinant nucleic acid molecule comprising sequences for an influenza virus HA segment from a first influenza virus isolate, which segment encodes an HA with an amino acid other than aspartic acid or glutamic acid at position 117 in HA2, wherein the numbering for HA2 residues is that for H1 HA2;
modifying the HA segment to encode an aspartic acid or glutamic acid at position 117 in HA2, thereby yielding a modified HA segment; and
contacting a cell with a vector comprising promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus PA segment DNA linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus PB1 segment DNA linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus PB2 segment DNA linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to the modified HA segment linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus NP segment DNA linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus NA segment DNA linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus M segment DNA linked to a transcription termination sequence, and a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus NS segment DNA linked to a transcription termination sequence; and
a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus PA, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus PB1, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus PB2, and a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus NP, and optionally a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus HA, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus NA, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus M1, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus M2, or a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus NS1 or a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus NS2;
in an amount effective to yield infectious influenza virus.
2. The method of claim 1 , wherein the PA, PB1, PB2, NP, NS, and M segments are from an influenza vaccine virus isolate.
3. The method of claim 1 , wherein the NA segment and the HA segment are from a different isolate than the PA, PB1, PB2, NP, NS, and M segments.
4. The method of claim 1 , wherein the NA gene segment and the HA gene segment are from the same influenza virus isolate as the PA, PB1, PB2, NP, NS, and M segments.
5. The method of claim 1 , wherein the PA, PB1, PB2, NP, NS, and M segments comprise sequences for at least one of the following: a PB1 having the amino acid sequence encoded by SEQ ID NO:2 or PB1 with at least 90% amino acid sequence identity to the PB1 encoded by SEQ ID NO:2; a PB2 having the amino acid sequence encoded by SEQ ID NO:3 or PB2 with at least 90% amino acid sequence identity to the PB2 encoded by SEQ ID NO:3; a PA having the amino acid sequence encoded by SEQ ID NO:1 or PA with at least 90% amino acid sequence identity to the PA encoded by SEQ ID NO: 1; a NP having the amino acid sequence encoded by SEQ ID NO:4 or NP with at least 90% amino acid sequence identity to the NP encoded by SEQ ID NO:4; a M1 and M2 having the amino acid sequence encoded by SEQ ID NO:5 or M1 and M2 with at least 90% amino acid sequence identity to the M1 and M2 encoded by SEQ ID NO:5; or a NS1 and NS2 having the amino acid sequence encoded by SEQ ID NO:6 or NS1 and NS2 with at least 90% amino acid sequence identity to the NS1 And NS2 encoded by SEQ ID NO:6.
6. The method of claim 1 , wherein the PA, PB1, PB2, NP, NS, and M segments comprise sequences for at least one of the following: a PB1 having the amino acid sequence encoded by SEQ ID NO:10 or PB1 with at least 90% amino acid sequence identity to the PB1 encoded by SEQ ID NO:10; a PB2 having the amino acid sequence encoded by SEQ ID NO:11 or PB2 with at least 90% amino acid sequence identity to the PB2 encoded by SEQ ID NO: 11; a PA having the amino acid sequence encoded by SEQ ID NO:12 or PA with at least 90% amino acid sequence identity to the PA encoded by SEQ ID NO: 12; a NP having the amino acid sequence encoded by SEQ ID NO:13 or NP with at least 90% amino acid sequence identity to the NP encoded by SEQ ID NO:13; a M1 and M2 having the amino acid sequence encoded by SEQ ID NO:14 or M1 and M2 with at least 90% amino acid sequence identity to the M1 and M2 encoded by SEQ ID NO:14; or a NS1 and NS2 having the amino acid sequence encoded by SEQ ID NO:15 or NS1 and NS2 with at least 90% amino acid sequence identity to the NS1 and NS2 encoded by SEQ ID NO:15.
7. The method of claim 1 , wherein the cell is an isolated mammalian cell.
8. The method of claim 7 , wherein the isolated mammalian cell is a Vero cell, an isolated human cell or an isolated hamster cell.
9. The method of claim 1 , wherein the HA gene segment is a H1, H2, H3, H5, H7, or H9 segment.
10. The method of claim 1 , wherein the HA2 that has an aspartic acid or glutamic acid at position 117 in HA2 has at least 80% amino acid sequence identity to one of SEQ ID Nos. 22-27.
11. A method to prepare an influenza virus with enhanced replication in Vero cells, comprising:
providing a vector comprising a recombinant nucleic acid molecule comprising sequences for an influenza virus HA segment from a first influenza virus isolate, which segment is modified to encode an HA with aspartic acid or glutamic acid at position 117 in HA2, wherein the numbering for HA2 residues is that for H1 HA2; and
contacting a cell with a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus PA segment DNA linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus PB1 segment DNA linked to a transcription termination sequence, a vector for comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus PB2 segment DNA linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to the modified HA segment linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus NP segment DNA linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus NA segment DNA linked to a transcription termination sequence, a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus M segment DNA linked to a transcription termination sequence, and a vector comprising a promoter that yields full length, genomic influenza virus RNA or its complement operably linked to an influenza virus NS segment DNA linked to a transcription termination sequence; and
a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus PA, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus PB1, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus PB2, and a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus NP, and optionally a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus HA, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus NA, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus M1, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus M2, a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus NS1 or a vector comprising a promoter that yields mRNA operably linked to a DNA segment encoding influenza virus NS2,
in an amount effective to yield infectious influenza virus.
12. The method of claim 11 , wherein the PB1, PB2, PA, NP, NS, and M segments in the vectors that yield full length, genomic influenza virus RNA or its complement are from the same influenza vaccine virus isolate.
13. The method of claim 11 , wherein the NA segment and the HA segment are from a different isolate than the PA, PB1, PB2, NP, NS, and M segments.
14. The method of claim 11 , wherein the cell is a Vero cell, an isolated human cell or an isolated hamster cell.
15. The method of claim 11 , wherein the HA segment is a H1, H2, H3, H5, H7, or H9 gene segment.
16. A method to prepare an influenza virus with enhanced replication in Vero cells, comprising:
providing an isolated influenza virus having a PA segment, a PB1 segment, a PB2 segment, a NP segment, a NS segment, a M segment, a NA segment, and a HA segment; and
modifying the HA segment to encode an aspartic acid or glutamic acid at position 117 in HA2, wherein the numbering for HA2 residues is that for H1 HA2, thereby yielding a modified influenza virus.
17. The method of claim 16 , further comprising introducing the modified virus into a cell.
18. The method of claim 16 , wherein the modified virus has enhanced replication in Vero cells relative to the isolated virus.
19. The method of claim 16 , wherein the modified virus has a titer at least one log greater in Vero cells than the isolated virus.
20. The method of claim 19 wherein the isolated virus has an alanine, asparagine, arginine or lysine at position 117 in HA2.